Researchers report that gene therapy and the diabetes drug metformin may be potential treatments for late-onset retinal degeneration (L-ORD), a rare, blinding eye disease. Scientists from the National Eye Institute (NEI), part of the NIH, generated a “disease-in-a-dish” model to study the disease. The findings (“AMPK modulation ameliorates dominant disease phenotypes of CTRP5 variant in retinal degeneration”) are published in Communications Biology.
“Late-onset retinal degeneration (L-ORD) is an autosomal dominant disorder caused by a missense substitution in CTRP5. Distinctive clinical features include sub-retinal pigment epithelium (RPE) deposits, choroidal neovascularization, and RPE atrophy. In induced pluripotent stem cells-derived RPE from L-ORD patients (L-ORD-iRPE), we show that the dominant pathogenic CTRP5 variant leads to reduced CTRP5 secretion,” write the investigators.
“In silico modeling suggests lower binding of mutant CTRP5 to adiponectin receptor 1 (ADIPOR1). Downstream of ADIPOR1 sustained activation of AMPK renders it insensitive to changes in AMP/ATP ratio resulting in defective lipid metabolism, reduced Neuroprotectin D1(NPD1) secretion, lower mitochondrial respiration, and reduced ATP production. These metabolic defects result in accumulation of sub-RPE deposits and leave L-ORD-iRPE susceptible to dedifferentiation.
“Gene augmentation of L-ORD-iRPE with WT CTRP5 or modulation of AMPK, by metformin, re-sensitize L-ORD-iRPE to changes in cellular energy status alleviating the disease cellular phenotypes. Our data suggests a mechanism for the dominant behavior of CTRP5 mutation and provides potential treatment strategies for L-ORD patients.”
“This new model of a rare eye disease is a terrific example of translational research, where collaboration among clinical and laboratory researchers advances knowledge not by small steps, but by leaps and bounds,” said Michael F. Chiang, MD, director of the NEI, part of the National Institutes of Health.
People with the disorder develop abnormal blood vessel growth and deposits of apolipoprotein E, which is involved in fat metabolism within the retina. Symptoms, including difficulty seeing in the dark and loss of central vision, usually appear around age 50–60. As L-ORD progresses, cells in the retinal pigment epithelium (RPE), a layer of tissue that nourishes the retina’s light-sensing photoreceptors, shrink and die. Loss of RPE leads to the loss of photoreceptors and in turn, to loss of vision.
The researchers were led by Kapil Bharti, PhD, who directs the NEI Ocular and Stem Cell Translational Research Section, and Kiyoharu (Josh) Miyagishima, PhD, and Ruchi Sharma, PhD, staff scientists in the section and leading authors of the study. They developed a laboratory model that uses induced pluripotent stem cells developed from skin (fibroblasts) to make RPE. They generated RPE from two siblings with L-ORD and, for comparison, RPE from two of the patients’ unaffected siblings who lacked the disease-causing mutation.
The patient-derived RPE shared key characteristics of the disorder in humans, including deposits of apolipoprotein E near the tissue, and abnormal secretions of vascular endothelial growth factor, a protein that stimulates blood vessel growth. The RPE cells also were dysmorphic, or deformed. By contrast, RPE from the unaffected siblings appeared normal. The researchers also found that the patient-derived RPE secreted far less of the mutant and the non-mutant CTRP5 protein compared with the models made from the unaffected siblings.
Using a computer modeling technique, the team showed that mutant CTRP5 was less likely to bind with cell receptors that help fine-tune fat metabolic regulation. Less receptor binding in turn leads to chronic activation of AMP-activated protein kinase (AMPK), a key regulator of energy homeostasis and fat metabolism.
They theorized that when AMPK is chronically activated, it becomes less sensitive to imbalances in energy demand and nutrient supply. When metabolic imbalances run unchecked, they alter lipid metabolism, which explains how apolipoprotein E accumulates as deposits near the RPE layer.
Testing that theory, the researchers chemically inhibited the chronically activated AMPK in the patient-derived RPE model and found fewer deposits of apolipoprotein E, and less abnormal secretion of vascular endothelial growth factor.
Next, using the patient-derived RPE model, they tested two potential treatment strategies: A gene therapy approach to encourage expression of normal CTRP5 in the RPE model, and the use of the diabetes drug metformin, which appears to modulate AMPK activity, re-sensitizing it to changes in cellular energy status. Both strategies prevented signs of L-ORD in RPE models.
“Importantly, we now have two potential strategies to disrupt the L-ORD disease process. While gene therapy may be years away, metformin is a drug that’s long been used to treat diabetes,” said Bharti, who with NEI collaborators is planning a clinical trial to test the drug in people with L-ORD.
Although L-ORD disease is rare, it shares similarities with other retinal degenerations like age-related macular degeneration, a leading cause of vision loss. The model developed for this study may prove helpful in understanding such age-related disease changes in the RPE.
The post Gene Study May Lead to New Late-Onset Retinal Degeneration Therapies appeared first on GEN - Genetic Engineering and Biotechnology News.protein cellular